Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) ...

Welcome to Madrigal Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. (Operator Instructions) As a reminder, today's conference call is being recorded. I'd like to introduce Ms. Tina ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...

Investing.com -- Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: NASDAQ: MDGL) rose 17% following the announcement of their fourth-quarter and full-year 2024 financial results, which included a ...

Reports Q4 revenue $103.3M, consensus $97.81M. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Looking back on 2024, I’m incredibly ...

Madrigal Pharmaceuticals (MDGL) reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra™ (resmetirom) in conjunction with diet and exercise for the treatment of adults with ...

The company's flagship product, Rezdiffra, approved for the treatment of non-alcoholic steatohepatitis (NASH), has been the primary driver of its recent financial performance and future growth ...